Clinical trial
Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection
NCT04416100 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection
- Lead sponsor
- Medical University Innsbruck
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- April 29, 2020
- Completion date
- April 28, 2022
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.